Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.

doi:10.1158/1078-0432.CCR-04-2424

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2005

Lakhani Sunil R, Reis-Filho Jorge S, Fulford Laura, Penault-Llorca Frederique, van der Vijver Marc, Parry Suzanne, Bishop Timothy, Benitez Javier, Rivas Carmen, Bignon Yves-Jean, Chang-Claude Jenny, Hamann Ute, Cornelisse Cees J, Devilee Peter, Beckmann Matthias W, Nestle-Krämling Carolin, Daly Peter A, Haites Neva, Varley Jenny, Lalloo Fiona, Evans Gareth, Maugard Christine, Meijers-Heijboer Hanne, Klijn Jan G M, Olah Edith, Gusterson Barry A, Pilotti Silvana, Radice Paolo, Scherneck Siegfried, Sobol Hagay, Jacquemier Jocelyne, Wagner Teresa, Peto Julian, Stratton Michael R, McGuffog Lesley, Easton Douglas F

Abstract excerpt

PURPOSE: To investigate the proportion of breast cancers arising in patients with germ line BRCA1 and BRCA2 mutations expressing basal markers and developing predictive tests for identification of high-risk patients. EXPERIMENTAL DESIGN: Histopathologic material from 182 tumors in BRCA1 mutation carriers, 63 BRCA2 carriers, and 109 controls, collected as part of the international Breast Cancer Linkage Consortium...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Germ-Line Mutation

Share to Keratins

Share to Multivariate Analysis

Share to Receptors, Estrogen

Share to Risk Assessment

Share to Sensitivity and Specificity

Source

Open in PubMed

Identifiers

PMID: 16033833
DOI: 10.1158/1078-0432.CCR-04-2424

Genes

BRCA1
BRCA2
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.PMID 16033833Read ↗

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.Semantic proximity Read ↗

Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.Semantic proximity Read ↗

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.Semantic proximity Read ↗

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.Semantic proximity Read ↗

CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry.Semantic proximity Read ↗

Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer.Semantic proximity Read ↗

Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers.Semantic proximity Read ↗

Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors.Semantic proximity Read ↗

The basal phenotype of BRCA1-related breast cancer: past, present and future.Semantic proximity Read ↗

Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.Semantic proximity Read ↗

Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers.Semantic proximity Read ↗

Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.